ArticleMolecular and clinical oncology2025
Disparities in long-term outcomes between benign and malignant diseases after Hartmann's procedure: A retrospective observational study.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long-term course following Hartmann's procedure (HP) has not yet been clarified. The present study aimed to compare the achievement of stoma reversal between benign and malignant diseases, and explore post-reversal long-term outcomes. Patients who underwent HP between June 2005 and December 2021 at a single center were retrospectively evaluated. The primary endpoint was the difference in stoma-reversal rate between benign and malignant diseases. The secondary endpoints were identification of the predictive factors for stoma reversal and comparison of stoma-free survival and anorectal functions after reversal between patients with benign and malignant diseases. Among 261 patients, the benign and malignant disease groups comprised 102 and 159 patients, respectively. Malignant disease (P=0.044), low Charlson's comorbidity index (P<0.001), urgent HP (performed as a lifesaving procedure; P=0.003) and home discharge (P<0.001) were significantly associated with stoma reversal in the multivariate analysis. Furthermore, cumulative stoma-reversal rate was significantly lower in the malignant disease than in the benign disease group (P<0.001). In 44 patients who underwent stoma reversal, the rate of stoma-free survival in the malignant disease group was significantly reduced compared with that in the benign disease group at 10 years after reversal (P=0.004). No significant between-group differences were observed regarding anorectal function (n=24). In conclusion, the achievement of stoma reversal and the stoma-free survival rate after reversal may be lower in patients with malignant disease than in those with benign disease; however, anorectal function after reversal may not be markedly different.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.